Biomx Stock Price, News & Analysis

BiomX Inc. (PHGE) is a clinical-stage company that develops natural and engineered bacteriophage (phage) therapies designed to target and destroy specific pathogenic bacteria involved in chronic diseases with substantial unmet medical needs. The company’s common stock trades on the NYSE American under the symbol PHGE, as disclosed in multiple Form 8-K filings. BiomX focuses on phage cocktails and personalized phage treatments and applies its proprietary BOLT (BacteriOphage Lead to Treatment) platform to discover and validate bacterial targets and customize phage compositions against those targets.

According to repeated descriptions in its press releases and SEC filings, BiomX is advancing phage-based therapeutics that address defined bacterial pathogens. Its programs have included candidates for infections associated with cystic fibrosis and for infections related to diabetic foot disease. BiomX states that it discovers and validates proprietary bacterial targets and then uses its BOLT platform to tailor phage compositions to those targets, reflecting an approach centered on pathogen specificity rather than broad-spectrum antibacterial strategies.

Core clinical programs and product candidates

BiomX has described several phage product candidates in its public communications:

• BX004: A fixed multi-phage cocktail developed for chronic pulmonary infections caused by Pseudomonas aeruginosa in people with cystic fibrosis (CF). Company disclosures note that P. aeruginosa is a major contributor to morbidity and mortality in CF patients. BiomX reported positive Phase 1b/2a data showing safety, tolerability and microbiologic activity, as well as improvement in pulmonary function associated with reduced P. aeruginosa burden in a predefined subgroup of patients with reduced lung function. BX004 received U.S. FDA Fast Track and Orphan Drug Designations. Later, BiomX initiated a Phase 2b randomized, double-blind, placebo-controlled, multicenter trial intended to evaluate lung function, bacterial load and quality-of-life measures over an 8‑week treatment period. The U.S. portion of this study was subsequently placed on clinical hold by the FDA due to questions about a third-party nebulizer device used to deliver BX004, with the company emphasizing that no concerns were raised about the BX004 drug product itself. Following internal analysis and Data Monitoring Committee (DMC) feedback regarding adverse events, BiomX elected to discontinue the BX004 Phase 2b trial.
• BX011: A next-generation fixed multi-phage cocktail targeting Staphylococcus aureus infections associated with diabetic foot infections (DFI). BiomX has reported positive feedback from the U.S. Food and Drug Administration (FDA) on the proposed clinical development pathway for BX011, indicating a clinical path in DFI. The company describes DFI as a serious bacterial infection that often develops from ulcers on the foot and as a leading cause of amputation in patients with diabetes. BX011 incorporates multiple proprietary phages, including phage previously evaluated in the company’s BX211 trial, to provide broad and potent coverage against S. aureus in DFI patients. Public disclosures indicate that BiomX plans to prioritize DFI as the lead indication for regulatory development, subject to the availability of financial resources.
• BX211: A phage treatment for diabetic foot osteomyelitis (DFO) associated with S. aureus. BiomX has reported statistically significant positive topline results from a Phase 2 trial of BX211 in DFO, including sustained reduction of ulcer size and improvements in ulcer depth, with separation from placebo starting at week 7. All patients in that study received standard of care, including systemic antibiotic therapy, over a 12‑week treatment period. These results form part of the rationale for advancing BX011 into DFI, which shares the same S. aureus pathogen.

Strategic focus and program evolution

BiomX describes itself as a clinical-stage company and has communicated several strategic shifts based on clinical data, regulatory feedback and financial resources. For BX004, the company initially advanced development through Phase 1b/2a and into a Phase 2b trial in CF patients with chronic P. aeruginosa infections. During this process, the FDA placed a clinical hold on the U.S. portion of the Phase 2b study to review data on the third-party nebulizer device used for drug delivery. BiomX worked with the device manufacturer to provide additional information and engaged in ongoing dialogue with the FDA. In parallel, an independent DMC reviewed safety data and recommended continuation of the study with an adjusted dosing regimen. Subsequently, however, BiomX determined that the projected timelines and resources required to pursue an alternative dosing strategy exceeded its available resources and decided to discontinue the BX004 Phase 2b trial.

Following the discontinuation of the CF Phase 2b study and in light of limited financial resources, BiomX reported that its Israeli subsidiary, BiomX Ltd., resolved to approve and authorize the filing of an application to commence insolvency proceedings under Israeli law. At the same time, the company indicated that it continues to own its BX011 program for diabetic foot infections, which is being conducted by Adaptive Phage Therapeutics, Inc., another subsidiary. BiomX has stated that, subject to sufficient financial and other resources, its focus will be on the development of bacteriophage-based therapeutics and advancing BX011 for S. aureus infections in DFI, while it evaluates strategic alternatives.

Regulatory interactions and designations

BiomX’s public updates emphasize frequent interaction with regulators, particularly the U.S. Food and Drug Administration. The company has reported:

• Fast Track and Orphan Drug Designations from the FDA for BX004 for CF patients with chronic P. aeruginosa lung infections.
• Written FDA feedback recognizing significant unmet medical need for therapies addressing chronic P. aeruginosa infection in CF, and outlining potential Phase 3 development pathways, including refined inclusion criteria and population enrichment strategies.
• Positive FDA feedback confirming a clear clinical development path for BX011 in DFI, including guidance consistent with established FDA guidance for DFI product development and comments on Chemistry, Manufacturing and Controls (CMC) that align with BiomX’s existing manufacturing and quality strategy. The company has stated that no additional non-clinical studies are expected for BX011 before a planned Phase 2a trial, subject to available resources.

In addition, BiomX has noted support from U.S. government-related entities for its S. aureus phage programs. Public disclosures state that development of phage therapies for S. aureus has been supported by non-dilutive funding from the U.S. Defense Health Agency (DHA) and Department of Navy funding under an Other Transaction Authority award through the Medical Technology Enterprise Consortium (MTEC), managed by the Naval Medical Research Command – Naval Advanced Medical Development.

Capital structure and corporate actions

BiomX has undertaken several corporate and financing actions that are relevant to PHGE stockholders and potential investors:

• Listing: Multiple Form 8-K filings confirm that BiomX’s common stock, par value $0.0001 per share, is listed on the NYSE American under the trading symbol PHGE.
• Reverse stock split: The company’s stockholders approved authorization for a reverse stock split at the 2025 Annual Meeting. The Board subsequently approved a one‑for‑nineteen reverse stock split of the outstanding common stock, with the company stating that the common stock would begin trading on a split-adjusted basis on NYSE American on November 25, 2025. Proportional adjustments were to be made to shares underlying outstanding equity awards, warrants and convertible preferred stock, and to the number of shares issued and issuable under stock incentive plans and certain agreements.
• Series Y Convertible Preferred Stock and warrants: In December 2025, BiomX entered into a Securities Purchase Agreement for a private placement of newly created Series Y Convertible Preferred Stock and warrants to purchase common stock. The company agreed to issue 3,300 shares of Series Y Preferred Stock with an aggregate stated value of $3.3 million and related warrants, for expected gross proceeds of approximately $3.0 million before fees and expenses. Each share of Series Y Preferred Stock has a stated value of $1,000, accrues dividends at a rate of 15% per annum payable quarterly, and has a maturity of one year from the closing date. The Series Y Preferred Stock is convertible into common stock at an initial conversion price of $2.00 per share, subject to adjustments and stockholder approval thresholds under NYSE American rules. The warrants issued in connection with the financing have an initial exercise price of $2.00 per share and a five‑year term, with similar adjustment and beneficial ownership limitations. A related Registration Rights Agreement requires BiomX to file a resale registration statement for the common shares issuable upon conversion of the Series Y Preferred Stock and exercise of the warrants.

BiomX has stated that it intends to use net proceeds from the private placement to support assessment of opportunities across its bacteriophage programs, including BX011 for S. aureus infections associated with DFI, and for general corporate purposes, including providing operational flexibility while the company evaluates strategic alternatives.

Corporate structure and subsidiaries

SEC filings identify BiomX Inc. as the registrant and refer to two key subsidiaries in the context of its operations:

• BiomX Ltd., an Israeli subsidiary that primarily conducted the BX004 Phase 2b study before its discontinuation. Following the decision to discontinue the study and in view of limited financial resources, the board of directors of BiomX Ltd. resolved to approve and authorize filing an application to commence insolvency proceedings under Israeli law.
• Adaptive Phage Therapeutics, Inc. (APT), described as a wholly owned subsidiary. APT was party to a lease agreement relating to premises in Gaithersburg, Maryland; a later amendment terminated that lease and settled related claims. BiomX has stated that its BX011 program for diabetic foot infections is being conducted by Adaptive Phage Therapeutics, Inc.

Risk and resource considerations

BiomX’s public statements highlight several factors that are relevant for understanding PHGE as a clinical-stage biotechnology issuer. The company has emphasized that its ability to pursue certain clinical development plans, including further work on BX011, is subject to the availability of sufficient financial and other resources. It has also disclosed cost-cutting measures, including workforce reductions, and has noted that it is reviewing strategic alternatives. These disclosures underscore that BiomX’s programs, and therefore the prospects associated with PHGE stock, are closely tied to clinical outcomes, regulatory feedback and financing capacity.

Overall, BiomX Inc. represents a specialized participant in the biological product manufacturing space, with a focus on phage-based therapeutics targeting specific bacterial pathogens in chronic conditions such as cystic fibrosis-related lung infections and diabetic foot disease. Its pipeline, platform and regulatory interactions are documented in its press releases and SEC filings, which provide the primary source of information for investors researching PHGE stock.